UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

Molecular cancer therapeutics, 2017-05, Vol.16 (5), p.850-860

2017

Volltextzugriff (PDF)

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

Molecular cancer therapeutics, 2017-11, Vol.16 (11), p.2586-2597

2017

Volltextzugriff (PDF)

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Cancer cell, 2019-07, Vol.36 (1), p.100-114.e25

2019

Volltextzugriff (PDF)

Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma

Scientific reports, 2017-12, Vol.7 (1), p.17993-17993, Article 17993

2017

Volltextzugriff (PDF)

Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound

ACS medicinal chemistry letters, 2015-06, Vol.6 (6), p.655-659

2015

Volltextzugriff (PDF)

Promoter Choice Determines Splice Site Selection in Protocadherin α and γ Pre-mRNA Splicing

Molecular cell, 2002-07, Vol.10 (1), p.21-33

2002

Volltextzugriff (PDF)

Abstract 312: Evidence of EZH2 dependent and independent mechanisms of tazemetostat treatment emergent resistance in models of diffuse large B cell lymphoma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.312-312

2016

Volltextzugriff (PDF)

Abstract B130: Elevated cancer-intrinsic type I interferon signaling confers a dependency on the RNA editor ADAR1

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.B130-B130

2019

Volltextzugriff (PDF)

Abstract 3345: Selective killing of SMARCA2- and SMARCA4-deficient tumors by inhibition of EZH2: In vitro and in vivo preclinical models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3345-3345

2017

Volltextzugriff (PDF)

Drug Discovery and Chemical Biology of Cancer Epigenetics

Cell chemical biology, 2017-09, Vol.24 (9), p.1120-1147

2017

Volltextzugriff (PDF)

RNA-modifying proteins as anticancer drug targets

Nature reviews. Drug discovery, 2018-06, Vol.17 (6), p.435-453

2018

Volltextzugriff (PDF)

Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis

Cancer cell, 2017-02, Vol.31 (2), p.286-299

2017

Volltextzugriff (PDF)

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

The lancet oncology, 2018-05, Vol.19 (5), p.649-659

2018

Volltextzugriff (PDF)

Identification of long-range regulatory elements in the protocadherin-α gene cluster

Proceedings of the National Academy of Sciences - PNAS, 2006-12, Vol.103 (52), p.19719-19724

2006

Volltextzugriff (PDF)

Cellular and Molecular Basis of Deiodinase-Regulated Thyroid Hormone Signaling

Endocrine reviews, 2008-12, Vol.29 (7), p.898-938

2008

Volltextzugriff (PDF)

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma

PloS one, 2016-07, Vol.11 (7), p.e0158888-e0158888

2016

Volltextzugriff (PDF)

Absence of Thyroid Hormone Activation during Development Underlies a Permanent Defect in Adaptive Thermogenesis

Endocrinology (Philadelphia), 2010-09, Vol.151 (9), p.4573-4582

2010

Volltextzugriff (PDF)

BLU-808, a Potent and Selective Small Molecule Inhibitor of Wild-type c-KIT for Mast Cell Disorders

Journal of allergy and clinical immunology, 2024-02, Vol.153 (2), p.AB62

2024

Volltextzugriff (PDF)

The chemical chaperones tauroursodeoxycholic and 4-phenylbutyric acid accelerate thyroid hormone activation and energy expenditure

FEBS letters, 2011-02, Vol.585 (3), p.539-544

2011

Volltextzugriff (PDF)

Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP

Genes & development, 2010-07, Vol.24 (13), p.1403-1417

2010

Volltextzugriff (PDF)

Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations

The Journal of biological chemistry, 2000-03, Vol.275 (12), p.8812-8816

2000

Volltextzugriff (PDF)

Abstract 1944: Tazemetostat displays synergistic antiproliferative activity with backbone therapies in preclinical models of AT/RT and MRT

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1944-1944

2017

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(55)
Dissertationen
(1)

Sprache

Englisch
(56)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(21)
Animals
(16)
Humans
(16)
Mice
(13)
Biochemistry & Molecular Biology
(8)
Cancer
(6)
Oncology
(6)
Cell Biology
(5)
Cells, Cultured
(5)
Enhancer Of Zeste Homolog 2 Protein - Antagonists & Inhibitors
(5)
Iodide Peroxidase - Metabolism
(5)
Male
(5)
Methylation
(5)
Mice, Knockout
(5)
Mutation
(5)
Cell Line, Tumor
(4)
Endocrinology & Metabolism
(4)
Gene Expression
(4)
Proteins
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma

Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound

Promoter Choice Determines Splice Site Selection in Protocadherin α and γ Pre-mRNA Splicing

Abstract 312: Evidence of EZH2 dependent and independent mechanisms of tazemetostat treatment emergent resistance in models of diffuse large B cell lymphoma

Abstract B130: Elevated cancer-intrinsic type I interferon signaling confers a dependency on the RNA editor ADAR1

Abstract 3345: Selective killing of SMARCA2- and SMARCA4-deficient tumors by inhibition of EZH2: In vitro and in vivo preclinical models

Reawakening of Human Fetal Hemoglobin and an Epigenetic Path to the Clinic for Sickle Cell Disease and Beta-Thalassemia: Identification of an Orally-Available, Potent, and Selective Euchromatic Histone Lysine Methyltransferase 1 and 2 (EHMT1/2) Inhibitor

Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma

Drug Discovery and Chemical Biology of Cancer Epigenetics

RNA-modifying proteins as anticancer drug targets

Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Identification of long-range regulatory elements in the protocadherin-α gene cluster

Cellular and Molecular Basis of Deiodinase-Regulated Thyroid Hormone Signaling

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma

Absence of Thyroid Hormone Activation during Development Underlies a Permanent Defect in Adaptive Thermogenesis

BLU-808, a Potent and Selective Small Molecule Inhibitor of Wild-type c-KIT for Mast Cell Disorders

The chemical chaperones tauroursodeoxycholic and 4-phenylbutyric acid accelerate thyroid hormone activation and energy expenditure

Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP

Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations

Abstract 1944: Tazemetostat displays synergistic antiproliferative activity with backbone therapies in preclinical models of AT/RT and MRT

Suchergebnisse filtern